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The human gastrointestinal tract harbours myriad bacterial species,
collectively termed the microbiota, that strongly influence human health.
Symbiotic members of our microbiota play a pivotal role in the digestion of
complex carbohydrates that are otherwise recalcitrant to assimilation.
Indeed, the intrinsic human polysaccharide-degrading enzyme repertoire is
limited to various starch-based substrates; more complex polysaccharides
demand microbial degradation. Select Bacteroidetes are responsible for the
degradation of the ubiquitous vegetable xyloglucans (XyGs), through the
concerted action of cohorts of enzymes and glycan-binding proteins encoded
by specific xyloglucan utilization loci (XyGULs). Extending recent (meta)
genomic, transcriptomic and biochemical analyses, significant questions
remain regarding the structural biology of the molecular machinery required
for XyG saccharification. Here, we reveal the three-dimensional structures of
an a-xylosidase, a b-glucosidase, and two a-L-arabinofuranosidases from
the Bacteroides ovatusXyGUL. Aided by bespoke ligand synthesis, our analyses
highlight key adaptations in these enzymes that confer individual specificity
for xyloglucan side chains and dictate concerted, stepwise disassembly of
xyloglucan oligosaccharides. In harness with our recent structural characteriz-
ation of the vanguard endo-xyloglucanse and cell-surface glycan-binding
proteins, the present analysis provides a near-complete structural view of
xyloglucan recognition and catalysis by XyGUL proteins.1. Background
The metabolism of complex carbohydrates in the distal gastrointestinal (GI)
tract is central to human nutrition and health [1,2]. It is widely understood
that a well-balanced human diet consists of a significant proportion of fruits
and vegetables, the cell walls of which are primarily (approx. 90% of the dry
weight) comprised of a structurally diverse array of intrinsically non-digestible
polysaccharides popularly referred to as ‘dietary fibre’ [1–5]. The human
genome is, however, remarkably bereft of genes encoding the enzymes
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ingest, with the exception of the a-glucans, amylose and amy-
lopectin, that constitute starch [6]. Even in this case, certain
structurally compact, recalcitrant forms, known as ‘resistant
starches’ (RS), may reach the colon intact [3]. Both RS and the
diverse non-starch polysaccharides (NSP) of plant cell walls
are instead metabolized, to various extents, by our symbiotic
gut microbiota. Microbial fermentation of monosaccharides
in the gut produces short chain fatty acids (SCFAs), which pro-
vide a notable proportion (up to 10%) of our daily caloric
intake. In addition, localized butyrate production is particu-
larly required to maintain a healthy colonic epithelium [7–9].
There is, therefore, intense current research focus on (and con-
siderable popular interest in) potential causal links between
imbalance of the microbiota (dysbiosis) and a wide array of
human diseases, including irritable bowel diseases, persistent
Clostridium difficile infection, metabolic syndrome, diabetes,
atopy and neurological disorders [10–14].
Thus, human health is crucially dependent on the popu-
lation dynamics of the gut ecosystem, which is, in turn,
rooted in the capacity of the microbiota to utilize the complex
carbohydrates that we are otherwise incapable of accessing
[15,16]. Strikingly, many individual microbiotal species,
especially from the phylum Bacteroidetes, possess the genetic
capacity to produce hundreds of predicted carbohydrate-
active enzymes (CAZymes) [6,17]. This tremendous diversity
is directly reflective of the natural structural complexity of
plant, fungal and animal oligosaccharides and polysaccharides
in the human diet [5,16]. Numerous (meta)genomic, tran-
scriptomic and proteomic studies are continuing to provide a
wealth of information on the genetic potential and dynamic
response of the human gutmicrobiomewith regard to complex
carbohydrate catabolism [9,17–22]. However, our functional
understanding of the molecular mechanisms fuelling this eco-
system is currently only in its infancy, due to a comparative
paucity of enzymology and structural biology [23,24].
Indeed, among glycoside hydrolases (GH) from all organisms,
biochemically and structurally characterized examples total
only approximately 5% and 0.5%, respectively, of known
open-reading frames (ORFs) [25]; these values are much
lower for gut bacterial species.
The two dominant phyla in the colon of healthy adult
humans are the Gram-positive Firmicutes and the Gram-nega-
tive Bacteroidetes [26], individual species of which have been
implicated as key contributors to the breakdown of NSP in
the diet [17,19,27,28]. Bacteroidetes are particularly notable
for organizing cohorts of CAZymes and binding, transport
and sensor/regulator proteins into contiguous polysaccharide
utilization loci (PULs) [23,29,30]. Bacteroidetes PUL complex-
ity generally scales with the monosaccharide and linkage
complexity of the cognate substrate, especially with regard to
the number of GHs and polysaccharide lyases (PLs)
[17,19,23]. As such, PULs often encode completemolecular sys-
tems for the specific utilization of individual polysaccharides.
Likewise, intimate coordination of substrate adherence and
initial backbone cleavage at the cell surface, followed by com-
plete oligosaccharide hydrolysis in the confines of the
periplasmic space, represents a particularly elegant evolution-
ary strategy to limit loss of monosaccharides to the competitive
gut environment [31] (figure 1).
Transcending ‘omics’ surveys of the gut microbiota, an
emergingmethodology for the in-depth functional characteriz-
ation of PULs combines bacterial genetics, biochemistry andenzymology, and structural biology. A growing number of
such system-based approaches have been used to elucidate
the complex molecular details of fructan [36], seaweed por-
phyran [37], yeast mannan [38] and cereal xylan [39]
utilization by symbiotic human gut Bacteroides species. In this
context, we recently reported the characterization of a novel
xyloglucan utilization locus (XyGUL) that confers Bacteroides
ovatus, and species harbouring syntenic XyGULs, with the abil-
ity to utilize this abundant vegetable polysaccharide across
sampled human populations [32]. In this work, the complete
biochemical and crystallographic characterization of the van-
guard endo-xyloglucanase responsible for initiating substrate
backbone cleavage was presented, in addition to biochemical
data revealing the substrate specificity of the six downstream
exo-glycosidases. Together, these data allowed us to outline a
general pathway for dietary xyloglucan saccharification to
monosaccharides for primary metabolism. Until now, how-
ever, molecular-level insight into xyloglucan oligosaccharide
(XyGO) recognition and hydrolysis by these key downstream
enzymes has been lacking. Here, we present the three-
dimensional structures of BoGH31, BoGH43A, BoGH43B and
BoGH3B, expanding our knowledge of the structural determi-
nants required for xyloglucan degradation (figure 1). Our
analyses highlight key adaptations in these enzymes that
confer their specificity for xyloglucan oligosaccharides, while
also providing a rationale for themaintenance of two divergent
genes coding for GH3 enzymes, and similarly two divergent
genes for GH43 family members, within the same PUL.2. Material and methods
2.1. Cloning, over-expression and structure
determination of BoGH31
For structural characterization, the gene encoding BoGH31 was
recloned from pET21a(GH31) [32] into a modified pET28a
vector (pET-YSBL3C) containing an N-terminal His6-tag for
immobilizedmetal affinitypurification (IMAC)and3C-cleavage
site to allow subsequent removal of the tag [40]. The GH31 ORF
was amplified fromthepET21a(GH31) template and cloned into
linearized pET-YSBL3C using the InFusion-HD cloning kit
(ClonTech), according to the manufacturer’s instructions, to
give pET-YSBL3C(GH31).
Chemically competent Escherichia coli TUNER(DE3) cells
were transformed with the pET-YSBL3C(GH31) vector and
grown in LB medium containing 50 mg ml21 kanamycin at
378C. Once the cells reached an OD600nm of 0.8–1.0, the temp-
erature was lowered to 168C and expression was induced by
the addition of isopropyl b-D-galactopyranoside (IPTG) to a
final concentration of 200 mM and the expression was allowed
to proceed overnight. Cells were harvested by centrifugation at
10 800g for 20 min at 48C. Spent medium was discarded and
the cells were resuspended in 5 volumes of Buffer A
(50 mM HEPES pH 7, 0.3 M NaCl, 10 mM imidazole). Cells
were lysed with four 20 s pulses of sonication at maximum
amplitude in an MSE Soniprep 150 sonicator on ice. Cell
debris was removed by centrifugation at 3900g in a cooled
bench top centrifuge and the cleared lysate was applied
directly to a 5 ml HisTrap FF Crude column (GE Healthcare).
After washing with 5–6 volumes of Buffer A, protein
was eluted with a linear gradient from 0 to 100% Buffer B
(50 mM HEPES pH 7, 0.3 M NaCl, 500 mM imidazole) over
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Figure 1. Summary of the xyloglucan saccharification system encoded by the BoXyGUL. (a) Gene organization of the BoXyGUL, coloured with reference to the
proteins shown in subsequent panels. GenBank locus tag numbers are indicated below each gene. (b) endo-Xyloglucanases GH5 (structure from [32]) and GH9
localized to the surface of the cell cleave long xyloglucan polysaccharides into smaller fragments, with glycan capture facilitated by cell-surface glycan-binding
proteins SGBP-A and SGBP-B (structures from [33]). (c) The resulting shorter oligosaccharides are imported into the periplasm via the TonB-dependent transporter
(TBDT) for further processing. (d ) exo-Glycosidases GH31, GH43A, GH43B and GH2 remove pendant xylosyl, arabinofuranosyl and galactosyl side chains. (e) GH3A and
GH3B b-glucosidases act from the non-reducing end liberating individual glucose residues. The oligosaccharides can be further hydrolysed, by these individual
enzymes, into monosaccharides. ( f ) The liberated sugars are imported into the cell and metabolized. See [34] for a detailed summary of XyG side-chain structures;
monosaccharides are represented using standard Consortium of Functional Glycomics symbols [35].
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containing BoGH31 were combined and concentrated to less
than 2 ml using a 50 kDa cut-off Sartorius concentrator
before being applied to a HiTrap 16/60 superdex 200 column(GE Healthcare), which had been equilibrated with 25 mM
HEPES pH 7, 100 mM NaCl and 1 mM DTT. After a void
volume of 40 ml, 2 ml fractions were collected and those
containing BoGH31 were combined and concentrated using a
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was determined to be 35 mg ml21 as judged by A280nm using
an extinction coefficient of 238735 M21 cm21 and a molecular
weight of 109 815.6 Da.
Crystals ofBoGH31were obtained by hanging drop vapour
diffusion (198C) using 0.2 M potassium thiocyanate, 14–20%
(w/v) PEG-3350 as mother liquor and were used for sub-
sequent structure determination. Crystals were cryo-cooled
for data collection at 100 K by plunging in liquid nitrogen
after a 30 s soak in mother liquor supplemented with 20%
ethylene glycol. Crystals of BoGH31 in complexwith a covalent
inhibitor, 5FIdoF [41,42], were obtained by soaking native crys-
tals in 10 mM (final) 5FIdoF supplemented with mother liquor
for 30 s, immediately prior to cryocooling. Diffraction data for
native BoGH31were collected at Diamond Light Source, beam-
line i04-1 at awavelength of 0.920 A˚, while data for the covalent
5FIdoF complex were collected at beamline i04 (also Diamond
Light Source, l ¼ 0.9795 A˚). All data were indexed and inte-
grated using XDS [43] with all subsequent processing steps
performed using the CCP4 software suite [44]. The structure
was solved by molecular replacement in MOLREP [44] using
the protein chain in PDB entry 2xvg as the search model. An
initial model was generated using ARP-WARP [45] before sub-
sequent model building and refinement were performed in
COOT [46] and REFMAC [47], respectively.2.2. Cloning, over-expression and structure
determination of BoGH43A
For structural characterization, the gene encoding BoGH43A
was recloned from pET21a [32] into pET28a containing
an N-terminal His6-tag for IMAC. The BoGH43A ORF was
amplified from the pET21a(BoGH43A) template and cloned
into linearized pET28a using the InFusion-HD cloning kit
(ClonTech) according to the manufacturer’s instructions.
Protein expression and purification were performed exactly as
described above for BoGH31. The final BoGH43A sample was
concentrated on a 30 kDa cut-off Sartorius concentrator to
103 mg ml21 as judged byA280nm using an extinction coefficient
of 105 450 M21 cm21 and a molecular weight of 57 965.1 Da.
Crystals of BoGH43A were obtained by hanging drop
vapour diffusion (198C) using 0.1 M Tris pH 7.2–7.8, 0.18 M
magnesium chloride and 12% (w/v) PEG-6000 as mother
liquor and were used for subsequent structure determina-
tion. Crystals were cryo-cooled for data collection at 100 K
by plunging in liquid nitrogen after a 30 s soak in mother
liquor supplemented with 20% ethylene glycol. Crystals of
BoGH43A in complexwithAraDNJandAraLOGwere obtained
by soaking native crystals in 10 mM (final) solutions of respect-
ive compounds supplemented with mother liquor for 60 min,
prior to cryocooling. Diffraction data for native BoGH43A
were collected at Diamond Light Source, beamline i04-1
at a wavelength of 0.920 A˚, while datasets for AraDNJ
and AraLOG complexes were both collected at beamline i03
(l ¼ 0.9795 A˚). All data were indexed and integrated using
XDS [43] with all subsequent processing steps performed
using the CCP4 software suite [44]. The structure was solved
by molecular replacement in PHASER [48] using the protein
chain from previously solved BoGH43B as the search model.
An initial model was generated using BUCCANEER [49,50]
before subsequent model building and refinement were
performed in COOT [46] and REFMAC [47], respectively.2.3. Over-expression and structure determination
of BoGH43B
Chemically competent E. coli BL21 (DE3) cells were trans-
formed with pET21a(BoGH43B) [32] and grown in LB
medium containing 100 mg ml21 ampicillin at 378C. Once the
cells reached anOD600 of 0.4–0.6, the temperaturewas lowered
to 168C and expression was induced by the addition of IPTG to
a final concentration of 100 mMand the expressionwas allowed
to proceed overnight. Cells were harvested by centrifugation at
10 800g for 20 min at 48C. Spent medium was discarded
and the cells were resuspended in 5 volumes of Buffer A
(50 mM HEPES pH 7, 0.5 M NaCl, 30 mM imidazole). Cells
were lysed with four 20 s pulses of sonication at maximum
amplitude in an MSE Soniprep 150 sonicator on ice. Cell
debriswas removed by centrifugation at 39 000g and the super-
natant was applied directly to a 5 ml HisTrap FF Nickel NTA
column (GE HEalthcare). After washing with five volumes of
Buffer A, protein was eluted with a linear gradient from 0 to
100% Buffer B (50 mMHEPES pH 7, 0.5 M NaCl, 300 mM imi-
dazole) over 20 column volumes, collecting 1.6 ml fractions.
Peak fractions containing BoGH43B were combined and con-
centrated to less than 1 ml using a 30 kDa cut-off Sartorius
concentrator before being applied to a HiTrap 16/60 superdex
200 column (GEHealthcare) which had been equilibrated with
10 mM HEPES pH 7, 250 mM NaCl. After a void volume
of 40 ml, 1.6 ml fractions were collected and those contain-
ing BoGH43B were combined, concentrated and buffer
exchanged with 10 mM HEPES pH 7 on a 30 kDa cut-off
Sartorius concentrator. Protein concentration was determi-
ned to be 10 mg ml21 as judged by A280nm using an
extinction coefficient of 102 790 M21 cm21 and a molecular
weight of 57 243.3 Da.
Crystals of BoGH43B were obtained by hanging drop
vapour diffusion using 0.2 M sodium acetate pH 5, 20–30%
PEG-3350 as mother liquor and they were used for sub-
sequent structure determination. Crystals were cryo-cooled
for data collection at 100 K by plunging in liquid nitrogen
after a 30 s soak in mother liquor supplemented with 20%
ethylene glycol. Diffraction data were collected at Diamond
Light Source, beamline i02 at a wavelength of 0.980 A˚. The
data were indexed and integrated using XDS [43] with all
subsequent processing steps performed using the CCP4 soft-
ware suite [44]. The structure was solved by molecular
replacement in PHASER [48] using the protein chain in
PDB entry 1yrz as the search model. The initial phases
were improved using PARROT [51] and an initial model gen-
erated using BUCCANEER [49,50] before subsequent model
building and refinement were performed in COOT [46] and
REFMAC [47], respectively.
2.4. Over-expression and structure determination
of GH3B
GH3B expression and purification from the pET21a(GH3B)
construct created by Larsbrink et al. [32] was performed as
described above for BoGH43B. The final sample was pre-
pared at 10 mg ml21 as judged by the A280nm using an
extinction coefficient of 142 670 M21 cm21 and a molecular
weight of 86 512.6 Da.
Crystals were obtained by hanging drop vapour diffusion
using 0.2 M sodium acetate and 15–25% PEG-3350 as the
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liquid nitrogen using mother liquor supplemented with 20%
ethylene glycol as the cryo-protectant prior to data collection
at Diamond Light Source, beamline i04-1 at a wavelength of
0.920 A˚. Indexing and integration of diffraction data was per-
formed with XDS [43] with all subsequent data processing
performed using the CCP4 software suite [44]. Data were
phased by molecular replacement in PHASER [48] using the
barley b-glucosidase structure 1ex1 [52] as the search model.
Phase improvement was performed using PARROT [51]
before generation of an initial model using BUCCANEER
[49,50]. Subsequent model building and refinement were
performed in COOT [46] and REFMAC [47], respectively.
TLS refinement using two TLS groups per protein chain was
invoked towards the end of structure refinement.
2.5. Synthesis of arabinofuranosidase inhibitors
2.5.1. General
1H and 13C nuclear magnetic resonance spectra were obtained
on Bruker ARX500 (500 MHz for 1H and 125 MHz for 13C)
or Bruker AV600 (600 MHz for 1H and 150 MHz for 13C)
spectrometers (see the electronic supplementary material).
Mass spectra were recorded with a Waters GCT Premier
spectrometer using electrospray ionization (ES).
2.5.2. (E) and (Z )-2,3,5-Tri-O-acetyl-L-arabinofuranose oxime (2)
Hydroxylamine hydrochloride (240 mg, 3.45 mmol) was
added to a solution of the hemiacetal 1 [53] (610 mg,
2.21 mmol) and pyridine (0.45 ml, 5.5 mmol) in MeOH
(20 ml) and the mixture was stirred at reflux (2 h). Con-
centration of the solution by co-evaporation with toluene
(3  15 ml) followed by flash chromatography of the residue
(6 : 4 EtOAc/hexanes) produced the presumed oxime 2 as a
white solid (575 mg, 94%). Rf 0.40 (7 : 3 EtOAc/hexanes). This
solid was used without further purification.
2.5.3. (Z )-2,3,5-Tri-O-acetyl-L-arabinonhydroximo-1,4-lactone (3)
1,8-Diazabicyclo[5.4.0]undec-7-ene (0.35 ml, 2.3 mmol) was
added to a solution of the oxime 2 (575 mg, 2.08 mmol)
and NCS (305 mg, 2.28 mmol) in CH2Cl2 (21 ml) at 2408C,
in such a way that the temperature did not rise above
2358C, and the resulting mixture was stirred at 2408C for
1 h before being allowed to warm to room temperature over
2 h. The resulting solution was quenched with water and
diluted with CH2Cl2 (20 ml). The organic layer was separated
and washed with water (3  15 ml), brine, dried (MgSO4), fil-
tered and concentrated. Flash chromatography of the residue
(3 : 2 EtOAc/hexanes) yielded the triacetate 3 as a colourless
oil (410 mg, 71%). Rf 0.38 (7 : 3 EtOAc/hexanes).
1H NMR
(500 MHz, CDCl3): d 6.96 (br s, 1H), 5.74 (d, 1H, J ¼
2.8 Hz), 5.22–5.20 (m, 1H), 4.68–4.63 (m, 1H), 4.42 (dd, 1H,
J ¼ 4.5, 12.0 Hz), 4.31 (dd, 1H, J ¼ 6.0, 12.0 Hz), 2.15 (s, 3H),
2.13–2.11 (m, 6H); 13C NMR (125 MHz, CDCl3): d 170.66,
169.89, 169.28, 154.26, 83.37, 74.90, 72.46, 62.39, 20.69, 20.65.
HRMS (ES): m/z ¼ 312.0683; [M þ Na]þ requires 312.0695.
2.5.4. (Z )-L-Arabinonhydroximo-1,4-lactone (AraLOG)
Saturated ammonia in MeOH (5 ml) was added to a solution
of the triacetate 3 (100 mg, 0.346 mmol) in MeOH (5 ml) at08C and the solution was allowed to stand (08C, 2 h). Concen-
tration of the solution followed by flash chromatography of
the residue (3 : 7 MeOH/EtOAc) yielded the title compound
(39 mg, 68%). Rf 0.37 (3 : 7 MeOH/EtOAc).
1H NMR
(600 MHz, D2O): d 4.70 (d, 1H, J ¼ 7.2 Hz), 4.39–4.33
(m, 1H), 4.20 (dd, 1H, J ¼ 7.2 Hz), 4.00–3.95 (m, 1H), 3.81
(dd, 1H, J¼ 4.8, 13.2 Hz); 13C NMR (150 MHz, D2O): d
159.00, 84.79, 73.95, 73.71, 59.99. HRMS (ES): m/z¼ 164.0551;
[Mþ H]þ requires 164.0559.
2.5.5. (Z )-O-(2,3,5-Tri-O-acetyl-L-arabinosylidene)amino
N-phenylcarbamate (4)
Phenyl isocyanate (50 ml, 0.46 mmol) was added to a solution
of the triacetate 3 (105 mg, 0.363 mmol) and Et3N (0.16 ml,
1.2 mmol) in THF (5 ml) at 08C and the solution was stirred
(08C, 2 h). Concentration followed by flash chromatography
of the residue (1 : 1 EtOAc/hexanes) produced the carbamate
4 as a colourless foam (90 mg, 57%). Rf 0.31 (1 : 1 EtOAc/
hexanes). 1H NMR (500 MHz, CDCl3): d 7.76 (br s, 1H),
7.49–7.44 (m, 2H), 7.36–7.30 (m, 2H), 7.14–7.09 (m, 1H),
5.86 (d, 1H, J ¼ 3.0), 5.24 (dd, 1H, J ¼ 2.5, 3.0 Hz), 4.77–4.74
(m, 1H), 4.46 (dd, 1H, J ¼ 4.5, 12.5 Hz), 4.34 (dd, 1H, J ¼ 6.0,
12.5 Hz), 2.20 (s, 3H), 2.15 (s, 3H), 2.14 (s, 3H); 13C NMR
(125 MHz, CDCl3): d 170.38, 169.70, 168.88, 157.69, 151.21,
137.00, 129.07, 124.14, 119.36, 85.25, 77.16, 74.70, 72.85,
62.02, 20.60, 20.52. HRMS (ES): m/z ¼ 409.1248; [M þ H]þ
requires 409.1247.
2.5.6. (Z )-O-(L-Arabinosylidene)amino N-phenylcarbamate
(AraPUG)
Saturated ammonia inMeOH (5 ml) was added to a solution of
the carbamate 4 (80 mg, 0.20 mmol) inMeOH (5 ml) at 08C and
the solution was allowed to stand (08C, 2 h). The resulting sol-
utionwas concentrated to yield awhite solid. Trituration of the
solid (1 : 4 : 95 H2O/MeOH/EtOAc) yielded the title com-
pound as a white powder (43 mg, 78%). Rf 0.26 (1 : 9 MeOH/
EtOAc). 1H NMR (600 MHz, (CD3)2SO): d 9.78 (br s, 1H),
7.52–7.47 (m, 2H), 7.32–7.26 (m, 2H), 7.03–6.99 (m, 1H),
6.21 (br s, 1H), 5.85 (br s, 1H), 5.14 (br s, 1H), 4.46 (d, 1H, J ¼
4.8 Hz), 4.26–4.22 (m, 1H), 4.01 (m, 1H), 3.71 (m, 1H), 3.58
(m, 1H); 13C NMR (150 MHz, (CD3)2SO): d 163.17, 151.81,
138.71, 128.75, 122.71, 118.58, 88.38, 74.45, 73.77, 59.91.
HRMS (ES): m/z ¼ 283.0928; [M þ H]þ requires 283.0930.
2.6. Binding constant determination for AraF inhibitors
Binding of two arabinofuranosidase inhibitors, AraDNJ and
AraLOG, to BoGH43A and BoGH43B was investigated by iso-
thermal titration calorimetry (ITC) in a MicroCal Auto-
ITC200 system (GE Healthcare/Malvern Instruments).
BoGH43A titrations were performed in 25 mM HEPES pH
7.0, 100 mM NaCl and 1 mM DTT, while BoGH43B titrations
used 25 mM HEPES pH 7.0, 100 mM NaCl. Ligands were
prepared by dilution in the identical buffer as used for
protein sample preparation. AraLOG binding could not be
detected to either BoGH43A or B with titrations performed
in triplicate at 258C, with 1 mM AraLOG titrated into
100 mM pure protein. An interaction between AraDNJ and
both proteins, however, could be detected but appeared to
be weak and so low c-value ITCs were performed to obtain
binding data [54]. Assays were conducted in triplicate at
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protein (more precise protein concentrations were measured
for each sample immediately before performing the titrations
and these values were used for data fitting in ORIGIN). To
obtain saturation, titrations were split into two runs, the
first consisting of a single 1 ml injection at the start of the
run (discarded during the analysis) followed by 19 2 ml
injections of ligand. At the end of this run 39 ml was removed
from the cell, the syringe was refilled with ligand and the
titration was continued with 20 additional 2 ml injections.
CONCAT32 (MicroCal) was then used to concatenate the
data together into a single titration. To account for heats of
dilution, an additional titration was performed in exactly
the same way, titrating ligand into buffer. These reference
data were then subtracted from all experimental data
which were subsequently used to calculate dissociation
constants (Kd) using the ORIGIN 7 software package by
fixing the N-value at 1.0 during the fitting (MicroCal, see
figure 3d ).3. Results and discussion
3.1. Structure of the a-xylosidase BoGH31
As with many of the glycoside hydrolase families represented
within the Bo xyloglucan PUL (XyGUL), GH31 forms a large
(currently over 3800 sequences) and functionally diverse col-
lection of enzymes, with many a-glucosidases, a-xylosidases
and a-galactosidases featuring prominently [25]. Within
XyGULs, GH31 a-xylosidases play an essential role removing
xylose from the non-reducing end of processed xyloglucan
oligosaccharides (illustrated in figure 1d ). Such activity per-
mits enzymatic access to the b-1,4-linked glucose moieties
of the XyGO backbone. Indeed, deletion of the gene encoding
GH31 from the XyGUL completely abrogates the ability of
B. ovatus to grow on XyG and XyGOs [32]. Consistent with
this role, the GH31 a-xylosidase present within the Bo XyGUL
(BoGH31) has been shown to be highly active against native
XyGO substrates (XXXG and XLLG, nomenclature according
to [34]), rather than disaccharide-configured activity probes,
such as Xyl-a-PNP [32], despite the presence of optimized
chemical leaving groups requiring little protonic assistance
from the enzyme. These observations suggest substrate binding
by XyGO-active GH31 enzymes to be a both complex and
highly specific process, requiring recognition and occupancy
of multiple sub-sites distal to the catalytic centre.
The crystal structure of BoGH31 was determined to a res-
olution of 1.5 A˚ by molecular replacement using the
coordinates of CjXyl31A, a functional homologue present in
Cellvibrio japonicus (PDB ID: 2xvg, see [55]), as the search
model (for X-ray data collection and refinement statistics,
see the electronic supplementary material, table S1). A struc-
tural comparison of the refined BoGH31 atomic model using
PDBEFOLD [56] revealed close similarity to several other GH31
enzymes, including YicI from E, coli (currently the only other
structurally characterized a-xylosidase [57]). However, by far
the closest structural match to BoGH31 was CjXyl31A (Z
score ¼ 33.1, with RMSD ¼ 1.15 A˚ across 888 matched Ca
positions). As observed for CjXyl31A, BoGH31 presents with
an extensive, modular structure featuring several accessory
domains appended to a well-conserved TIM barrel-like struc-
ture (figure 2a) (for a full description of terms and domainnomenclature see [55]). The catalytic core of BoGH31 is com-
posed of residues 384 to 758, which form the central (b/a)8
(TIM) barrel fold and harbour the active site (discussed
below). The domains decorating the central catalytic unit
include an N-terminal b-sandwich domain formed by resi-
dues 16 to 213 with additional strands contributed by
residues 363 to 383 when the peptide chain returns from a
PA14 domain (residues 214 to 362). The presence of PA14
has been observed previously for GH31 in CjXyl31A and is
believed to contribute to the recognition and binding of
extended XyGO substrates, as was indicated by NMR spec-
troscopy and molecular docking studies [55,58]. C-terminal
to the central catalytic unit, are two additional domains—the
C-terminal proximal (residues 759–839) and distal (residues
840–954) b-sandwiches. While these accessory regions can
be thought of as distinct subdomains, extensive interactions
and packing of secondary structure elements against the cen-
tral (b/a)8 barrel are strongly suggestive of a low-flexibility,
monolithic structure.
The location of the BoGH31 active site and identity of
the catalytic amino acids were confirmed through analysis
of a covalent enzyme-glycoside intermediate formed bet-
ween crystals of native BoGH31 and a nucleophile-trapping
glycosyl fluoride, 5-fluoro-b-L-idosyl fluoride (5FIdoF)
(figure 2a–c). Within the complex structure, 5FIdoF forms
an a-glycosidic linkage to the side-chain carboxylate of
Asp553 at the centre of the (b/a)8 barrel. 5FIdoF makes
H-bonding interactions to Asp553, Arg613, Asp630 (O2 of
the sugar ring), His709 and a highly coordinated water mol-
ecule positioned between Asp630 and Asp659 (O3) and
Asp441 (O4 and the axially positioned F5 atom). Interest-
ingly, the enzyme-bound 5FIdoF shows significant
distortion away from the 1C4 ground state expected for
L-sugars, appearing in a 1S3 conformation. Such a confor-
mation is also reflected in various other covalent
intermediates with GH31 enzymes, including CjXyl31A in
complex with 5-fluoro-a-D-xylosyl fluoride (5FXylF; also
1S3, see 2xvk [55]) and CjAgd31B, a GH31 a-1,4-transglucosy-
lase, in complex with 5-fluoro-a-D-glucosyl fluoride (5FGlcF;
ligand appears midway between 4C1 and
1S3, see 4ba0 [59]).
The BoGH31 covalent glycosyl-enzyme intermediate struc-
ture lends further support to the role of the PA14 domain in
ligand binding [55]. This domain is in close proximity to the
enzyme-bound 5FIdoF, with the side chain of Trp316 approxi-
mately 6.5 A˚ from the ligand (figure 2d ). Furthermore, a
fortuitously bound HEPES molecule, present in the protein
buffer, can also be observed in the active site pocket below
the plane of the 5FIdoF sugar ring and bridging the gap
between ligand and PA14 (figure 2c). Within xyloglucan
from both dicot and solanaceous species, side-chain xylose
moieties are linked a-1,6 to the glucan backbone. Thus back-
bone sugars occupying the þ1, and other potential positive
sub-sites, would also highly likely be coordinated below the
plane of a21 xyloside, extending across and out of the catalytic
(b/a)8 barrel. The positioning of HEPES therefore appears
prescient, with the piperazine ring of the ligand engaged in a
van der Waals’ stacking interaction with Trp513 (catalytic
domain) from above, and Trp316 of PA14 from below. The
positioning of these aromatic side chains, in addition to numer-
ous other amino acids capable of forming hydrogen bonds,
is highly suggestive of a carbohydrate-binding motif, and
therefore a direct role for PA14 in the coordination of extended
XyGO substrates. A homologous role was proposed for the
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Figure 2. BoGH31 a-xylosidase overall and active site structure. (a) Overall structure of BoGH31 coloured by domain: N-terminal b sandwich in blue, the PA14
domain in purple, TIM barrel domain in gold, C-terminal proximal b-sandwich in green and C-terminal distal b-sandwich in red. The location of the active site
revealed by the covalent glycosyl-enzyme intermediate is shown as sticks coloured by atom type with green carbons. (b) Mechanism of formation of the glycosyl-
enzyme intermediate for the BoGH31–5FIdoF complex. (c) Wall-eyed stereo view of the active site pocket. The active site nucleophile (Asp553) and 5FIdoF are
coloured with green carbon atoms, with the surrounding active site side chains shown with gold carbon atoms. (d ) Wall-eyed stereo view of the wider active site
with the additional fortuitous HEPES molecule (white carbon atoms) shown revealing the likely role of the PA14 domain (purple) in extending the active site pocket
to allow binding of longer xyloglucan oligosaccharides.
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CjXyl31A from the saprophyte C. japonicus [55,58].3.2. Structures of the a-L-arabinofuranosidases
BoGH43A and BoGH43B
GH43 is a large and diverse family of CAZymes with mem-
bers identified with b-xylosidase, a-L-arabinofuranosidase,
arabinanase, xylanase, galactan 1,3-b-galactosidase, a-1,2-
L-arabinofuranosidase, exo-a-1,5-L-arabinofuranosidase,
exo-a-1,5-L-arabinanase and b-1,3-xylosidase activities.
There are two GH43 family members represented in the
B. ovatus xyloglucan PUL: BoGH43A and BoGH43B [32].
Both enzymes have demonstrable activity on L-Araf-a-PNP,
though BoGH43A was considerably more active, and both
are thought to be responsible for the removal of pendant arabi-
nofuranoside side chains from solanaceous xyloglucan
substrates, thereby converting S to X for further processing
by the a-xylosidase and other members of the PUL [32].3.2.1. Synthesis of arabinofuranosidase inhibitors
To aid in the structural characterization of the BoGH43A and
BoGH43B active sites, two new potential inhibitors for theseenzymes were synthesized. The compounds were prepared
incorporating an sp2-hybridized carbon at carbon-1, which
is thought to allow the carbohydrate ring to potentially
adopt a conformation that is similar to the geometry of the
transition state of glycosidase-catalysed reactions [60]. The
synthesis of these inhibitors proceeded from the hemiacetal
1 (scheme 1) [53]. Treatment of the hemiacetal with hydroxy-
lamine hydrochloride yielded the presumed mixture of
oximes 2, which were used without purification and
converted to the hydroximolactone 3 in good overall yield.
The inhibitor AraLOG was then prepared by treating 3 with
saturated ammonia in methanol. Taking the hydroximolac-
tone 3 and treating with phenyl isocyanate furnished the
phenyl carbamate 4. Deprotection of the carbamate 4 under
similar conditions used to prepare AraLOG gave AraPUG
in good yield.
3.2.2. BoGH43A structure
The structure of BoGH43A was determined to be 1.6 A˚ by
molecular replacement using the structure of BoGH43B
described below as the search model (for X-ray data collection
and refinement statistics, see the electronic supplemen-
tary material, table S2). Typical of all GH43s, BoGH43A has
a two-domain architecture, consisting of an N-terminal
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Scheme 1. Synthesis of the putative a-L-arabinofuranosidase inhibitors AraLOG and AraPUG as well as the structure of the iminosugar AraDNJ. (a) HONH2.HCl,
C5H5N, MeOH; (b) NCS, DBU, CH2Cl2; (c) NH3/MeOH (d ) PhNCO, Et3N, THF.
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the catalytic active site, and a C-terminal b-sandwich domain
(residues 322 to 522) which is frequently observed, though
can be replaced by carbohydrate binding modules in some
family members (see [61] for example) (figure 3a). Structural
comparisons using PDBEFOLD [56] reveal close overall matches
to other GH43s including XynB from Bacillus subtilis subsp.
subtilis strain 168 (BsXynB, 1yif; Z score ¼ 17.8, with
RMSD ¼ 1.44 A˚ across 478 matched Ca positions) and XynB
from Bacillus halodurans C-125 (BhXynB, 1yrz; Z score ¼ 17.7,
RMSD ¼ 1.45 A˚ across 473 matched Cas), which all share the
same two-domain architecture.
Within the native BoGH43A structure, a TRIS molecule
from the crystallization solution was observed bound in a
shallow, enclosed pocket proposed to form the BoGH43A
21 sub-site. Soaking of native BoGH43A with two putative
inhibitors, AraDNJ [62] and AraLOG, yielded respective
enzyme–ligand complexes, confirming this as the active site
(figure 3b). Disappointingly, no complexes were obtained
with AraPUG, despite the use of high concentrations of
inhibitor. AraDNJ was able to displace TRIS from the 21
sub-site and appeared bound in a low-energy 3E con-
formation typical of iminosugar ‘furanose’ inhibitors. The
side-chain carboxylate of Asp140 (O3 and O4 positions), the
backbone amino group of Ala94 (O4) and the OD2 atom of
Asp34 all directly coordinated the inhibitor (figure 3b).
GH43 members typically contain three highly conserved
acidic residues in their active sites to impart activity [63].
Together with Asp34 as the general base, which activates
water to attack the anomeric carbon, Glu189 is ideally
poised as the general acid, while Asp140 completes the triplet
of residues and is important for modulating the pKa and
orienting the general acid for catalysis. The positions of
these residues are absolutely conserved with other GH43
members.
For the AraLOG complex, repeated soaking at concen-
trations of up to 25 mM AraLOG for several hours failed to
displace TRIS from the 21 sub-site. Rather, AraLOG was
instead observed at the þ1 site, which would normally beoccupied by xylose moieties in the XyGO substrate
(figure 3c). The AraLOG complex therefore highlights key
interactions at this þ1 sub-site, with the inhibitor stacking
against Tyr187 while also H-bonding directly to the side
chains of Glu210 and Glu189. In the light of the inability of
AraLOG to displace TRIS from the active site, ITC (in the
absence of Tris) was used to probe the affinity of both
BoGH43A and BoGH43B (discussed below) for these inhibitors.
AraDNJ binds to BoGH43A with Kd ¼ 35+4 mM (figure 3d),
while AraLOG binding was too weak to be measured using
this technique, consistent with its inability to displace TRIS
during crystal soaking.
3.2.3. BoGH43B structure
Despite significant functional overlap with BoGH43A,
BoGH43B, the second a-L-arabinofuranosidase present in the
BoXyGUL, shares just 41% sequence identity with BoGH43A
and appears to be significantly less active on the substrates
tested [32]. The structure of BoGH43B was determined to
2.3 A˚ resolution by molecular replacement using a b-1,4-
xylosidase from B. halodurans (PDB ID 1yrz) as the search
model (electronic supplementary material, table S3). Remark-
ably, given their apparent differences at the amino acid level,
the structure of BoGH43B appears extremely similar to that of
BoGH43A, which can be superimposed onto BoGH43B, using
GESAMT [44], with an RMSD of 1.24 A˚ over 482 amino acid
residues (figure 4a). Comparison of tertiary folds reveals few
significant differences between the two paralogues, with the
most obvious being the presence of a metal binding site, occu-
pied by calcium, towards the C-terminus of BoGH43B. Such an
equivalent site appears entirely absent within BoGH43A. In
some GH43 members, addition of divalent cations within the
catalytic site has led to increased activity and stability for
these enzymes [64–66]. However, the Ca2þ-binding site in
BoGH43B is located in the C-terminal b-sandwich domain,
on the opposite side of the molecule from the active site, and
similar sites in other family members have not been implicated
in catalysis to date [63].
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Figure 3. Overall structure and inhibitor binding to BoGH43A a-L-arabinofuranosidase. (a) Overall structure of BoGH43A; the N-terminal catalytic domain is coloured
purple and C-terminal b-sandwich domain is coloured blue. The location of the active site is indicated by the position of AraDNJ shown in stick representation
coloured by atom type with green carbons. (b) Wall-eyed stereo view of the active site in the BoGH43A-AraDNJ complex. The final 2Fo-Fc map for the ligand is
shown contoured at 1s in blue. The hydrogen bonding interactions made by the inhibitor are shown as black dashed lines. (c) Wall-eyed stereo view of the active
site for BoGH43A-AraLOG complex. Binding of the AraLOG inhibitor (yellow carbon atoms) was too weak to displace TRIS (white carbon atoms) from the21 sub-site
and instead occupies þ1, revealing key stacking interactions with Tyr187 and other conserved residues. (d ) ITC thermogram showing the binding of AraDNJ to
BoGH43A in solution giving a Kd of 35+ 4 mM.
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with the same inhibitors used for BoGH43Awere unsuccessful.
ITC was used to determine the affinity of BoGH43B for
AraDNJ and AraLOG. BoGH43B bound AraDNJ with a Kd of
111+6 mM (figure 4c), while the affinity for AraLOG was too
weak to be measured, as observed for BoGH43A. This weaker
binding affinity for AraDNJ also appears consistent with the
lower specific activity of BoGH43B for xyloglucan oligosacchar-
ides when compared to its counterpart [32]. Superposition of
apo-BoGH43B with AraDNJ-BoGH43A reveals that the three
residues implicated in catalysis (Asp38, Asp148 and Glu198
in BoGH43B) are absolutely conserved. The only difference in
the BoGH43B 21 sub-site is the replacement of Phe93
(in BoGH43A) with a tyrosine residue in BoGH43B. The þ1
sub-site occupied by AraLOG in BoGH43A, however, is
considerably different. AraLOG stacks against Tyr187 inBoGH43A, which is replaced by Ser196 in BoGH43B. This vari-
ation means the active site pocket in BoGH43B is considerably
more open than in its XyGUL paralogue, possibly resulting in
weaker substrate binding affinity and hence lower specific
activity against authentic XyGO substrates. The reasoning that
B. ovatus should harbour two GH43 members in its XyGUL
remainsunclear, but thedifferences in theactive site architecture
away fromthe21 sub-sitemay represent the adaptationof these
enzymes to specific substrate sources, possibly with alternate
Araf structures on XyG branch termini [34].
3.3. Structure of b-glucosidase BoGH3B
GH3 represents a large family of over 8000 sequences in the
CAZy database. Like GH43, there are two GH3 members
(BoGH3A and BoGH3B) present in the Bo XyGUL, both of
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Figure 4. Structural comparison of BoGH43B with BoGH43A. (a) Overall superposition of BoGH43B (orange) with BoGH43A (purple) revealing a highly conserved
tertiary structure arrangement between the two proteins, even though they share only 41% sequence identity. The largest differences between the two proteins are
restricted to altered positioning of loops linking secondary structure elements. (b) Comparison of the arrangement of the active site residues between BoGH43B
(orange carbons) and BoGH43A (purple carbons). The positions of AraDNJ (green carbons) and AraLOG (yellow carbons) from the BoGH43A structure are shown. The
21 sub-site is mainly conserved between the two proteins, but the þ1 sub-site surrounding the AraLOG ligand is significantly different between BoGH43A and B,
most notably Tyr187, which stacks against AraLOG in BoGH43A, is replaced by Ser196 in BoGH43B. (c) Representative ITC thermogram for the measurement of AraDNJ
binding to BoGH43B. Weaker binding was observed to this enzyme compared to BoGH43A giving a Kd of 111+ 6 mM, providing a rationale for our inability to
obtain a BoGH43B-AraDNJ complex structure.
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specific activities. Despite apparently duplicated biochemical
function, the two enzymes appear to have diverged signifi-
cantly, sharing only 27% sequence identity at the amino acid
level [32]. As for the GH43 enzymes, the functional significance
of maintaining two seemingly identical b-glucosidases
remains unclear, and so we aimed to structurally characterize
both orthologues.
While GH3B proved readily amenably to crystallization,
unfortunately, despite intense efforts, a similarly crystalliz-
able form of GH3A could not be produced. The structure of
GH3B was determined to 2.3 A˚ resolution (electronic sup-
plementary material, table S4) by molecular replacement
using the coordinates of barley b-glucosidase (PDB ID:
1ex1, see [52]) as the search model. BoGH3B comprises
a three-domain architecture, consisting of an N-terminal
(TIM) barrel-like domain (residues 26 to 419), a central a/b
sandwich domain (residues 420 to 660) and a fibronectin
type-III (FN-III)-like domain at the C-terminus (residues
661–782) (figure 5a). Structural comparisons using PDBEFOLD
[56] revealed close structural matches to several other GH3
members, the closest match being to a single protomer of a
novel homodimeric GH3 identified in a metagenomic analy-
sis of unnamed soil bacteria (PDBs: 3u48 and 3u4a), withRMSDs of 1.22 and 1.21 A˚ over 742 and 739 residues, respect-
ively. The dimeric organization of this novel enzyme appears
potentially important for function, with a large, flexible loop
reaching over from one protomer to contact the substrate and
fully assemble the active site of the neighbouring molecule.
There is no suggestion of such a dimerization occurring for
GH3B, which also shows close matches to more typical
monomeric family members including the family 3 b-glucosi-
dases from Thermatoga neapolitana (PDBs: 2x42 and 2x41 with
RMSDs of 1.49 A˚ and 1.50 A˚, respectively, both over 715 resi-
dues) [68] and Hypocrea jecorina/Trichoderma reesei (PDBs: 4i8d
and 3zyz with RMSDs of 1.42 and 1.50 A˚ over 711 and 713
residues, respectively) [69]. All of these structures share the
same three-domain architecture as GH3B, though maximum
identity is no more than 36% at the primary sequence level.
BoGH3B was found to co-purify with glucose in its active
site (figure 5b). This could readily be modelled with a 4C1
chair conformation, highlighting the position of the 21 sub-
site. As is typical for hydrolytic GH3 members, the active
site is formed largely by residues from the core TIM barrel,
with additional interactions further contributed by loops
from the a/b sandwich domain (figure 5b). GH3 members
are well-known to employ the classical Koshland double-dis-
placement, configuration-retaining mechanism [70]. Within
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Figure 5. Structural analysis of BoGH3B. (a) Overall structure of BoGH3B with the N-terminal TIM-barrel-like domain coloured pink, the a/b sandwich domain
coloured purple and the C-terminal FN-III like domain coloured green. The position of the active site is indicated by the presence of glucose, represented as sticks
with green carbon atoms. (b) Wall-eyed stereo view of the active site in BoGH3B. The final 2Fo-Fc map is shown contoured at 1s as a blue mesh around the glucose
molecule that co-purified with the protein. All side chains within 4 A˚ of glucose are shown as sticks with the carbons coloured according to the domain from which
they are provided. (c) Surface representation of BoGH3B around the active site pocket revealing a tight entry to the active site resulting from the presence of Trp315
and Trp458, the positions of which are indicated in stick representation. The surface is coloured by domain as for the previous panels and the surface has been
clipped for clarity. See the electronic supplementary material, figure S1a, for stereo view. (d ) Surface representation of the active site pocket from T. neopolitana GH3
(PDB 2x41), shown from the same perspective as for BoGH3B in (c). The surface is coloured with the TIM-barrel domain shown in green and the a/b domain
coloured magenta. This enzyme lacks an equivalent residue to Trp458, and the side chain of Trp243 (shown in stick representation) is positioned differently giving a
much more open structure to the active site entrance. See the electronic supplementary material, figure S1b, for stereo view. (e) Structure-based sequence alignment
of BoGH3B with other GH3 family members identified through PDBEFOLD [56]—sections of the alignment have been removed for brevity and breaks are indicated by
diagonal double lines across the alignment (the full sequence alignment can be found in the electronic supplementary material, figure S2). The sequence for
BoGH3A was added to the structural alignment using MAFFT [67]. The secondary structure elements (coloured by domain as previously) and residue numbers
from BoGH3B are indicated along the top of the alignment, with sequence similarity indicated by the shading behind the individual amino acids. Below the aligned
sequences, residues lining the21 sub-site are indicated with green triangles, the catalytic nucleophile and acid/base are indicated by magenta stars and tryptophan
side chains narrowing the active site structure in BoGH3B are shown with orange circles.
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and acid/base (Glu534) residues can be observed in close
proximity to the glucose moiety, poised for nucleophilic
attack. Together with residues forming the 21 sub-site, these
interactions appear well conserved, and are maintained in sev-
eral other GH3–glucose complexes [52,68,69]. Away from the
21 sub-site, the exterior surface structure of the GH3B active
pocket deviates from themost closely related homologues, pre-
senting as a more closed structure (figure 5c) similar to that
seen in the distantly related barley b-glucosidase [52]. The
barley enzyme shows quite narrow specificity for b-1,3- and
b-1,4-linked glucans, while closer overall structural matches
to BoGH3B, including the T. neapolitana and H. jecorina
enzymes described above, show much broader activities
against b-1,2-, b-1,3-, b-1,4- and b-1,6-linked disaccharides
[68,69]. Such promiscuous catalytic functionality has been
suggested to result from the more open active site architecture
maintained by this group, allowing diverse linkages and
longer substrates to be accommodated (figure 5d) [68]. GH3B
has significant activity for glucose-only oligosaccharides but
displays far weaker activity on xyloglucan-derived oligos,
which retain their xylose side chains [32]. Similar to barley b-
glucosidase, such observations might suggest that the narrow-
ing of the active site cleft could be responsible for the high
specificity of BoGH3B towards b-1,4-linked glucans.
Analysis of residues forming the GH3B þ1 sub-site
reveals more discernable differences between the two paralo-
gous GH3 members in the BoXyGUL. Sequence analysis
suggests poor conservation of two aromatic residues,
Trp315 and Trp458 (BoGH43B numbering), which through
p-stacking interactions appear to form the narrow GH3B
þ1 sub-site. Although the equivalent to Trp315 is maintained
in GH3A (Trp274), an equivalent to Trp458 appears absent.
We hypothesize therefore that GH3A may present a more
open active site architecture, leading to a similar rationale
in the presence of two GH3 genes to that described above
for the BoXyGUL GH43 paralogues. The closed active site
pocket in GH3B appears to result in higher affinity inter-
actions with longer ‘cello-oligosaccharides’, suggesting that,
as for the two BoGH43 members, subtle differences in the
active site architecture might confer adaptations to specific
substrates. Again, such a proposal would thus provide a
reasonable molecular basis for the maintenance of two
highly similar genes in the same operon.4. Conclusion
The absence, within the human genome, of genes encoding
enzymes able to metabolize a significant proportion of the
complex polysaccharides present in our own diet has
thrown into sharp relief the importance of our internal
microbial ecosystems [6,71]. The capacity of the gut micro-
biota to utilize these large, intractable molecules dictates
both the composition and correct functioning of this large
non-somatic dietary organ, and as such has a direct and cru-
cial impact upon the health of the human host [72]. Recent
systems biology approaches have highlighted the many
niche roles played by diverse bacteria within the human
microbiota [36–39]. While genomics and metagenomics
initiatives continue apace, generating increasing amounts of
sequence data, further approaches linking sequence data to
biological function are essential to understanding theadaptations of individual species that allows them to fulfil
their symbiotic role within the human digestive system.
Xyloglucan degradation is a niche occupied primarily by
the Bacteroidetes, and we have previously highlighted the
importance of the specific XyGUL encoded by B. ovatus to
allow this bacterium to compete for nutrients [32]. Central
to this analysis was the tertiary structural characterization
of the vanguard endo-xyloglucanase, BoGH5, that catalyses
the first backbone hydrolysis step required for xyloglucan
polysaccharide metabolism. Recently, we have revealed the
key role that two cell-surface glycan-binding proteins
(SGBPs) encoded by the XyGUL play in XyG utilization
through combined genetic, biophysical and crystallographic
analyses [33].
Here, we have significantly extended our knowledge of the
structural biology of the XyGUL through crystallography of
several exo-glycosidases encoded by the BoXyGUL. This
analysis provided insight into the structural features within
these enzymes that allow them to interact with and degrade
their xyloglucan oligosaccharide substrates. Furthermore,
our analysis highlights differences in the structures of two
GH43 proteins, which display similar biochemical properties
but aremaintainedwithin the operon nonetheless. Such obser-
vations suggest that these paraloguesmayplay subtly different
roles during the degradation of xyloglucans from different
sources, or may function most optimally at different stages in
the catabolism of XyGOs, for example before or after hydroly-
sis of certain side-chain moieties. While we were unable to
determine a structure for BoGH3A, our structural and
sequence analysis of BoGH3B has also allowed us to highlight
further potential differences between these two enzymes
encoded by the operon. Together with existing biochemical
data, our analyses of the three-dimensional structures, andvar-
ious enzyme-inhibitor complexes, of BoGH31, BoGH43A,
BoGH43B and BoGH3B provide molecular-level insight into
the stepwise breakdown of xyloglucan by the BoXyGUL.
Characterization of key adaptions within these enzymes pro-
vides a firm rationale for alternate specificities for XyGOs
that may also allow for more efficient degradation of xyloglu-
can from different sources within the gut.
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